{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8"},{"groupId":"OG001","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"A Treatment-emergent Adverse Events (TEAE) is defined as an AE that occurs, having been absent before the first dose of study drug or has worsened in severity or seriousness after initiating the study drug until 47 days after the last dose of the study drug. Serious AEs with an onset or worsening 48 days or more after the last dose of study drug, if considered related to study treatment. are also TEAEs. TEAEs were assessed in the Safety Analysis Set at data cut-off date of 01 Nov 2022.","groups":[{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"T-DXd 5.4 mg/kg Q3W"},{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).","id":"OG001","title":"T-DXd 6.4 mg/kg Q3W"}],"paramType":"NUMBER","populationDescription":"The Safety Analysis Set (SAS) included all randomized/registered subjects who received at least 1 dose of study treatment. Subjects were summarized according to treatment received.","reportingStatus":"POSTED","timeFrame":"From first dose administration to data cut off, up to approximately 19 months.","title":"Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer","type":"SECONDARY","unitOfMeasure":"percentage of participants"}